Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
First and only PARP inhibitor to improve overall survival in early breast cancer
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated
